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The family of Cu II -bis(thiosemicarbazone) complexes inhibits Complex I of the respiratory chain without apparent release of bioavailable Cu ions.
INTRODUCTION

The family of neutral, planar and lipophilic bis(thiosemicarbazonato)Cu
II complexes (Cu(btsc), Figure 1A ) shows potential as therapeutics in the treatment of cancer and neurodegenerative diseases. 1 We and others have also shown recently that these complexes exert potent antibacterial activities against medically significant bacterial pathogens. [2] [3] [4] The present model for the biological action of Cu(btsc) complexes as developed from studies in mammalian cells has highlighted their ability to increase intracellular Cu pools. Figure 1A) . 5, 7 In the case of Cu(gtsm), the reduction potential is physiologically 
2,10,11
Alternative models for mechanisms of action that do not rely on the release of bioavailable Cu ions have also been proposed. Cu(btsc) complexes interact strongly with lipid bilayers, where they would not encounter cytosolic reductants. 2, 12, 13 Furthermore, Cu(btsc)
complexes are able to persist in their intact and unreduced forms and accumulate as hydrophobic aggregates inside the reducing cytosolic environment. 12, 14 These intact forms of Cu(btsc) may exert a cellular effect. For instance, Cu(gtsm) derivatives inhibit DNA synthesis inside the nucleus presumably by intercalation and/or binding to DNA topoisomerases.
14,15
Cu(atsm), which is not thought to release bioavailable Cu ions, was neuroprotective in animal models of Parkinson's disease due to, at least in part, modulation of peroxynitrite-mediated toxicity.
16
We have recently explored the antimicrobial activities of Cu(btsc) complexes against the bacterial pathogen Neisseria gonorrhoeae. homologues display key variations in structural organisation, molecular details of catalysis and susceptibility to various inhibitors, but they nonetheless share common defining features.
They are usually membrane-bound, multi-subunit, multi-cofactor enzyme complexes that provide primary entry points for electrons into the electron transport chain to O 2 ( Figure   2A ). 17 Complex I homologues catalyse electron transfer from NADH to ubiquinone (Coenzyme Q) and this process is coupled with the translocation of protons across the lipid bilayer. Ubiquinol (QH 2 ) subsequently provides reducing equivalents for downstream 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Figure 1) .
In the presence of BSA, both Cu(gtsm) and Cu(atsm) suppressed NADH:O 2 OR activity reproducibly and the extent of inhibition increased with compound concentration. Dose-response curves for Cu(gtsm) estimated an average I 50 value of 15.6 µM ( Figure 4 and Supporting Table 1 ). By contrast, addition of Cu(atsm) only led to minor losses of activity ( Figure 4 ). Due to poor solubility of Cu(atsm) at concentrations above 100 µM, an I 50 value could not be extrapolated reliably. The relative inhibitory powers of Cu(gtsm) and Cu(atsm) matched our earlier observations in intact mitochondria ( Figure 3 ) and in whole, live bacteria. 2 We have reported previously that Cu(atsm) also strongly suppressed the activity of NADH dehydrogenases in N. gonorrhoeae. 2 However, this effect was likely due to aggregation of Cu(atsm) in the BSA-free buffer. Consequently, inhibition of the gonococcal NADH dehydrogenases by Cu(atsm) was removed upon addition of BSA (data not shown).
Taken together, these results confirmed that Cu(gtsm) was a more effective inhibitor of NADH:O 2 OR activity than was Cu(atsm). Based on these findings, subsequent experiments were performed with Cu(gtsm) only. As Cu(gtsm) inhibited oxidation of NADH but only slightly affected oxidation of succinate, it was likely that Complex I was the primary target of Cu(gtsm) action.
Due to relative ease of manipulation, the mechanism of inhibition of bacterial and (Figure 4) appeared to correlate well with the "copper-boosting" model ( Figure 1B ; Figure 7A 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 Metallomics Accepted Manuscript the estimated average I 50 value for Zn(gtsm) was 36.4 µM, ca. 2 times higher than that of Cu(gtsm) (Figure 8 and Supporting However, the I 50 value for the inhibition of NADH:O 2 OR activity by Cu(gtsm) did not change with the amount of SMPs over a ten-fold range ( Figure 10A ). In addition, progress traces NADH oxidation in the presence of Cu(gtsm) were linear over 5 min (Supplementary Figure 3) . Correspondingly, pre-incubation of Cu(gtsm) with SMPs for 20 min prior to addition of NADH did not produce a shift in the dose-response curve within experimental Metallomics Accepted Manuscript error ( Figure 10B ). Likewise, recovery of NADH:O 2 OR activity upon dilution did not require an initial incubation time ( Figure 9B ). These results confirmed that Cu(gtsm) is not an aggregation-based inhibitor. 
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To identify the site of inhibition by Cu(gtsm), NADH oxidation was decoupled from O 2 consumption using azide, a Complex IV inhibitor ( Figure 2A and Table 1 ). Complex I function was subsequently monitored using artificial electron acceptors ( Figure 11A ). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 60
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Complex I inhibitors, as exemplified by rotenone ( Figure 11D ). Rotenone is thought to act as a non-competitive inhibitor, i.e. it inhibits the rates of ubiquinone reduction but does not block access by ubiquinone to its reduction site. 30 Unlike rotenone, preliminary kinetic analyses indicated that Cu(gtsm) may be a competitive inhibitor of Complex I (Supplementary Figure 4) . In this case, Cu(gtsm) and ubiquinone may compete for the same binding site. However, the precise mechanism of Complex I inhibition by Cu(gtsm) must await further studies.
Like Cu(gtsm), curve-fitting of the dose-response curve for Zn(gtsm) in Figure 8 yielded n = 1.1 (Supporting Table 1 ). Thus, it is likely that Cu(gtsm) and Zn(gtsm) share the same binding site. However, due to significant spectral overlap with NADH (Supplementary 
CONCLUSION
The results reported here add to the growing body of evidence that the intact complex may be important in the overall cellular activity of Cu(btsc) complexes and thus must not be overlooked. Although the present work has focused on mitochondrial Complex I, we have confirmed our findings using Complex I homologues from N. gonorrhoeae and E. coli (manuscript in preparation).
Notably, the electron transport chain in bacteria is located in the cytoplasmic membrane and thus it is readily accessible to the environment. Indeed, exposure to Cu(gtsm) led to an immediate inhibition of aerobic respiration in intact live bacteria and eventually loss of bacteria viability.
2 By contrast, in eukaryotes such as cancer and neuronal cells, Cu(gtsm) must cross the plasma membrane, the cytosol and the outer mitochondrial membrane to , micromolar concentrations are required to achieve a toxic effect in eukaryotic cells.
10
The intracellular fate of Cu(gtsm) and related derivatives in eukaryotes appears to be cell-specific but the reasons for these variations are not fully understood.
12,21,31-34
Nevertheless, interaction of Cu(btsc) with the mitochondria inside live cells has been reported previously. For instance, intracellular reduction of Cu(atsm) and Cu(ptsm) (R 1 = H, R 2 = CH 3
in Figure 1A , E m -280 mV vs. SHE) in tumour cells was shown to occur specifically in the mitochondria and not in the cytosol. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Cu(Egta) complex was generated in situ using CuCl 2 and 2 molar equivalent of Egta.
EXPERIMENTAL
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The free Egta ligand without any CuCl 2 was used as control but it had no detectable effect on NADH oxidase activity.
Isolation of intact mitochondria. Intact mitochondria were isolated from rat liver tissues. Liver tissues were obtained from 6-or 7-week-old male Wistar rats. The following steps were performed at 4 o C in Buffer A (Na-Hepes (20 mM), Tris-Cl (4 mM), mannitol (220 mM), sucrose (70 mM), Edta (1 mM), pH 7.4). Tissues were washed with BSA (1 mg mL -1 )
to remove blood and fatty contaminants, homogenised also in the presence of BSA, and finally centrifuged (600 g, 30 min) to remove unhomogenised tissues and nuclear debris. The supernatant fraction was collected and re-centrifuged (10,000 g, 30 min). The brown, mitochondria-rich pellet was washed twice without BSA and resuspended finally in BSA-free buffer to a final concentration of 40 mg protein mL -1 . Mitochondrial preparations were kept on ice and used immediately for respiratory assays. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 60
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Mitochondrial respiration. Respiration rates were measured at 35 o C using an S1/Mini Clark-type oxygen electrode (Hansatech Instruments) in conjunction with an Oxytherm control unit. Each assay contained Tris-Mops buffer (10 mM, pH 7.4), KCl (125 mM), Egta (1 mM), potassium phosphate (100 µM), and BSA (1 mg mL -1 ). Sodium glutamate, sodium malate and sodium succinate (2.5 mM each) were used as required.
Cu(atsm) and Cu(gtsm) (100 µM each) were added to the assay mixture prior to addition of mitochondria. Consumption of O 2 was initiated by addition of mitochondria (1.5 mg mL -1 ).
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